JMP Securities Cuts Dynavax Technologies (NASDAQ:DVAX) Price Target to $31.00

Dynavax Technologies (NASDAQ:DVAX) had its target price lowered by JMP Securities from $33.00 to $31.00 in a research report sent to investors on Wednesday morning,Benzinga reports. The firm currently has a market outperform rating on the biopharmaceutical company’s stock.

DVAX has been the subject of a number of other reports. StockNews.com downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday. William Blair restated an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 21st. The Goldman Sachs Group cut their price objective on Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating for the company in a report on Thursday, April 17th. Finally, HC Wainwright restated a “buy” rating and set a $31.00 target price on shares of Dynavax Technologies in a report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $24.00.

Dynavax Technologies Stock Down 2.9 %

NASDAQ:DVAX opened at $9.41 on Wednesday. The stock has a 50-day simple moving average of $12.24 and a 200 day simple moving average of $12.55. Dynavax Technologies has a 52-week low of $9.28 and a 52-week high of $14.63. The company has a market cap of $1.15 billion, a PE ratio of 52.28 and a beta of 1.26. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.14). The business had revenue of $68.16 million for the quarter, compared to the consensus estimate of $70.01 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. On average, sell-side analysts expect that Dynavax Technologies will post 0.32 EPS for the current fiscal year.

Hedge Funds Weigh In On Dynavax Technologies

Institutional investors and hedge funds have recently modified their holdings of the stock. E Fund Management Co. Ltd. raised its stake in Dynavax Technologies by 4.6% in the 4th quarter. E Fund Management Co. Ltd. now owns 17,627 shares of the biopharmaceutical company’s stock worth $225,000 after purchasing an additional 771 shares in the last quarter. Summit Investment Advisors Inc. raised its position in shares of Dynavax Technologies by 7.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 13,782 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 904 shares in the last quarter. Choreo LLC grew its position in Dynavax Technologies by 3.2% during the first quarter. Choreo LLC now owns 34,828 shares of the biopharmaceutical company’s stock worth $452,000 after buying an additional 1,065 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in Dynavax Technologies by 19.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock worth $83,000 after acquiring an additional 1,076 shares during the period. Finally, Sanctuary Advisors LLC raised its holdings in Dynavax Technologies by 6.3% in the 4th quarter. Sanctuary Advisors LLC now owns 18,836 shares of the biopharmaceutical company’s stock valued at $245,000 after acquiring an additional 1,109 shares in the last quarter. 96.96% of the stock is currently owned by institutional investors and hedge funds.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.